Navigation path

Community Register of medicinal products

Community register of medicinal products for human use
AUTHORISED  

Product information
Invented name: Rivastigmine Sandoz   
Auth. number : EU/1/09/599
INN : Rivastigmine
ATC: N - Nervous system
N06 - Psychoanaleptics
N06D - Anti-dementia drugs
N06DA - Anticholinesterases
N06DA03 - Rivastigmine
(See WHO ATC Index)
Indication: Symptomatic treatment of mild to moderately severe Alzheimer´s dementia and of mild to moderately severe dementia in patients with idiopathic Parkinson´s disease.
Marketing Authorisation Holder: Sandoz Pharmaceuticals GmbH
Raiffeisenstraße 11, D-83607 Holzkirchen, Deutschland

  EPAR and active package presentations

Package presentations

The section of the Community Register "Package presentations" will no longer be updated as from 2 November 2012.
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which continues to be available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/12/2009 Centralised - Authorisation EMEA/H/C/1183 (2009)10328 of 11/12/2009
31/08/2010 Centralised - Variation EMEA/H/C/1183/IB/1
Updated with Decision(2011)5384 of 20/07/2011
25/07/2011 Centralised - Variation - (2011)5384 of 20/07/2011
04/10/2011 Centralised - Variation EMEA/H/C/1183/IA/4/G
Updated with Decision(2012)1182 of 17/02/2012
21/02/2012 Centralised - Variation EMEA/H/C/1183/II/5, 6/G (2012)1182 of 17/02/2012
06/11/2012 Centralised - Variation EMEA/H/C/1183/II/11 (2012)8007 of 31/10/2012